HCV Management in Primary Care: Closing Treatment Gaps in Rural and Underserved Communities
- Module 1: HCV in Pregnancy: Screening, Treatment, and Management
- Module 2: HCV and Injection Drug Use: An Evidence-Based Approach to Treatment
- Module 3: HCV and Alcohol Use Disorder: A Multidisciplinary Approach to Management
To access the activities, select a module title in the blue box above. Then, enter your name, email address, and degree in the appropriate fields of the form, and click Continue.
Jointly provided by Postgraduate Institute for Medicine and RME Collaborative.
Release Date: January 31, 2022
Expiration Date: January 31, 2023
Estimated Time to Complete: 15 minutes per module
The introduction of direct-acting oral antiviral agents (DAAs) has transformed the treatment of hepatitis C virus (HCV), leading to high cure rates and short treatment durations. Despite these advances, the use of new DAAs in rural and underserved communities is low owing to limited access to specialty care, distance, and travel time. Expanding primary care capacity to treat HCV infection is therefore critical to improving access and reducing barriers to treatment. This case-based CME/CE activity series will review current testing recommendations, therapy selection, and follow-up care after the completion of treatment. Strategies to improve multidisciplinary care and overcome barriers in rural and underserved areas will also be explored.
Nancy S. Reau, MD, FAASLD, AGAF
Richard B. Capps Chair of Hepatology
Professor, Department of Internal Medicine
Division of Digestive Diseases and Nutrition
Rush Medical College
Section Chief of Hepatology
Associate Director of Organ Transplantation
Rush University Medical Center
Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.
Module 1: HCV in Pregnancy: Screening, Treatment, and Management
- Apply current treatment recommendations and the latest clinical evidence to appropriately treat patients with HCV
Module 2: HCV and Injection Drug Use: An Evidence-Based Approach to Treatment
- Differentiate between available treatment regimens for HCV based on their clinical safety and efficacy
Module 3: HCV and Alcohol Use Disorder: A Multidisciplinary Approach to Management
- Implement strategies to overcome barriers and improve multidisciplinary HCV care in rural and underserved communities
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Module 1: 0.25 AMA PRA Category 1 Credit™
- Module 2: 0.25 AMA PRA Category 1 Credit™
- Module 3: 0.25 AMA PRA Category 1 Credit™
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours. Designated for 0.25 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
- Module 1: 0.25 contact hour
- Module 2: 0.25 contact hour; 0.25 pharmacotherapy credit
- Module 3: 0.25 contact hour
HOW TO OBTAIN CREDIT
If you wish to receive CME/CE credit, please follow the below steps for each module you complete:
- Read the entire activity.
- Go to cmeuniversity.com. In the “Find Post-Test/Evaluation by Course” field at the top of the page, enter the course code 16888.
- Select the module you completed and fill out the activity evaluation form. A certificate of participation will be available to download/print immediately.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine and RME Collaborative adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Nancy S. Reau, MD, FAASLD, AGAF, has disclosed the following relationships: consultant for AbbVie, Inc., Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., and Merck & Co., Inc.; grant/research support from GENFIT, Intercept Pharmaceuticals, Inc., and Shire Pharmaceuticals.
Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.
This activity is supported by an independent educational grant from AbbVie, Inc.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or email@example.com.
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine via email at firstname.lastname@example.org.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
COMPUTER SYSTEM REQUIREMENTS
- Operating system: Windows or Macintosh
- Supported browsers: HTML5-capable browser – Internet Explorer 11, Microsoft Edge, Firefox 27+, Chrome 30+, Safari 9+
- Hardware: computer, smartphone, or tablet
- Broadband Internet connection: high-speed connection preferable
©RME Collaborative, a division of Talem Health, LLC 2022. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.